- Home
- KURA vs PHAT Comparison
KURA vs PHAT Comparison
Compare KURA & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KURA
- PHAT
- Stock Information
- Founded
- KURA 2014
- PHAT 2018
- Country
- KURA United States
- PHAT United States
- Employees
- KURA N/A
- PHAT N/A
- Industry
- KURA Biotechnology: Biological Products (No Diagnostic Substances)
- PHAT Biotechnology: Pharmaceutical Preparations
- Sector
- KURA Health Care
- PHAT Health Care
- Exchange
- KURA Nasdaq
- PHAT Nasdaq
- Market Cap
- KURA 561.9M
- PHAT 640.9M
- IPO Year
- KURA N/A
- PHAT 2019
- Fundamental
- Price
- KURA $7.34
- PHAT $10.24
- Analyst Decision
- KURA Strong Buy
- PHAT Strong Buy
- Analyst Count
- KURA 13
- PHAT 5
- Target Price
- KURA $24.45
- PHAT $16.40
- AVG Volume (30 Days)
- KURA 1.5M
- PHAT 1.1M
- Earning Date
- KURA 08-07-2025
- PHAT 08-07-2025
- Dividend Yield
- KURA N/A
- PHAT N/A
- EPS Growth
- KURA N/A
- PHAT N/A
- EPS
- KURA N/A
- PHAT N/A
- Revenue
- KURA $83,279,000.00
- PHAT $114,039,000.00
- Revenue This Year
- KURA $125.04
- PHAT $194.40
- Revenue Next Year
- KURA $83.75
- PHAT $103.23
- P/E Ratio
- KURA N/A
- PHAT N/A
- Revenue Growth
- KURA N/A
- PHAT 1049.82
- 52 Week Low
- KURA $5.41
- PHAT $2.21
- 52 Week High
- KURA $21.57
- PHAT $19.71
- Technical
- Relative Strength Index (RSI)
- KURA 67.38
- PHAT 63.28
- Support Level
- KURA $5.45
- PHAT $8.03
- Resistance Level
- KURA $6.74
- PHAT $11.19
- Average True Range (ATR)
- KURA 0.38
- PHAT 0.63
- MACD
- KURA 0.10
- PHAT 0.16
- Stochastic Oscillator
- KURA 82.17
- PHAT 69.98
About KURA Kura Oncology Inc.
Kura Oncology Inc is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The company's pipeline consists of small molecule drug candidates targeting cancer signaling pathways.
About PHAT Phathom Pharmaceuticals Inc.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.